Bristol-Myers Squibb Co Profit Margin

Data as of August 04, 2026

How It's Calculated

What This Means

Bristol-Myers Squibb Co's profit margin of 12.3% is solid for many industries, though norms vary widely in Pharmaceuticals.

About Bristol-Myers Squibb Co

Bristol-Myers Squibb Co (BMY) operates in the Pharmaceuticals sector, specifically in Pharmaceuticals. With a market capitalization of about $133.41B, it ranks as a large-cap stock — a major established company.

Shares recently traded near $65.47, within a 52-week range of $42.52 to $65.66 (-0.3% from the high, +54.0% from the low). Beta of 0.23 indicates relatively lower volatility versus the market.

Trailing profit margin is about 12.3%, signaling a solid profit margin for its industry.

Understanding This Metric

Profit margin connects income-statement quality to valuation. For Bristol-Myers Squibb Co, trailing margin summarizes how much revenue converts to net profit after costs. In Pharmaceuticals, margins differ by business model — software and services often run higher margins than capital-intensive industries. Track margin trends across quarters; a stable or improving margin can support earnings durability, while sharp declines may warrant deeper review of guidance and competition.

Using This Number in Practice

At about 12.3% trailing profit margin, Bristol-Myers Squibb Co (BMY) is in a range often seen among mature operators in its industry. For large revenue bases, even a one-point margin move can shift earnings materially, so trend matters as much as the spot reading.

When comparing BMY to alternatives, combine margin with return on equity, revenue growth, and valuation. Use our margin calculator for scenario work, and browse the BMY metrics hub plus sector peers in the comparison section above.

Sector Comparison

Among Pharmaceuticals names on our S&P 100 coverage, Bristol-Myers Squibb Co's profit margin of 12.3% can be compared with peers such as LLY (35.0%), JNJ (21.5%), MRK (13.6%). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Pharmaceuticals stocks.

Key Takeaways

• BMY is grouped in the Pharmaceuticals sector for peer comparisons.
• Recent beta of 0.23 suggests lower-than-market price sensitivity.
• Trailing profit margin of 12.3% provides context for how much earnings support the headline multiple.

Related Tools & Guides

Explore calculators and guides connected to this metric, or view all metrics for BMY.

Other BMY Metrics

Frequently Asked Questions